Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center-Reference-Cited by-同舟云学术

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center

Published:2016-07 Issue:7 Volume:22 Page:1275-1283
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Rowe R. Grant,Guo Dongjing,Lee Michelle,Margossian Steven,London Wendy B.,Lehmann Leslie

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference34 articles.

1. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy;George;Transpl Infect Dis,2010

2. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease;Miller;Blood,1986

3. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation;Broers;Blood,2000

4. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant;Goodrich;Ann Intern Med,1993

5. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation;Reusser;Blood,2002

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation;Clinical Transplantation;2024-06

2. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment;Nature Communications;2024-04-18

3. Disparities in Cytomegalovirus Infection Rates by Race and Ethnicity among Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients at a Single Center;Transplantation and Cellular Therapy;2024-03

4. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia;Pediatric Blood & Cancer;2024-01-12

5. Retrospective Evaluation of Cystatin C as a Measure of Renal Function in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Foscarnet for Cytomegalovirus Reactivation;Pediatric Infectious Disease Journal;2023-12-28